We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+34.71%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$364M
AUM Growth
+$141M
Cap. Flow
+$79.4M
Cap. Flow %
21.83%
Top 10 Hldgs %
87.22%
Holding
22
New
4
Increased
2
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$78.3M
2
CHRS icon
Coherus Oncology
CHRS
+$12.3M
3
STML
Stemline Therapeutics, Inc.
STML
+$4.12M
4
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.15M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$12.5M
2
RDUS
Radius Health, Inc.
RDUS
+$6.92M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$4.76M
4
ALXA
Alexza Pharmaceuticals Inc
ALXA
+$166K

Sector Composition

Rank Sector Weight
1 Healthcare 74.65%
2 Miscellaneous 25.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$74.3M 20.45%
+1,749,999
New +$78.3M
ADVM
2
DELISTED
Adverum Biotechnologies
ADVM
$73.1M 20.1%
138,274
– –
ANAC
3
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$38M 10.46%
1,178,474
– –
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.52B
$21.2M 5.84%
1,744,356
– –
GWPH
5
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$21.1M 5.81%
311,853
– –
LRMR icon
6
Larimar Therapeutics
LRMR
$421M
$16.7M 4.59%
45,123
– –
DYAX
7
DELISTED
DYAX CORPORATION
DYAX
$14.1M 3.87%
1,000,659
-1,000,200
-50% -$12.5M
CHRS icon
8
Coherus Oncology
CHRS
$226M
$13.1M 3.6%
+870,269
New +$12.3M
HRTX icon
9
Heron Therapeutics
HRTX
$63M
$11M 3.03%
1,095,734
– –
RDUS
10
DELISTED
Radius Health, Inc.
RDUS
$9.08M 2.5%
233,294
-291,706
-56% -$6.92M
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
$8.56M 2.36%
500,000
– –
STML
12
DELISTED
Stemline Therapeutics, Inc.
STML
$6.08M 1.67%
356,400
+285,400
+402% +$4.12M
OCRX
13
DELISTED
Ocera Therapeutics, Inc.
OCRX
$4.48M 1.23%
703,730
– –
ZSPH
14
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$4.16M 1.14%
100,000
– –
NBSE
15
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$3.98M 1.09%
1,193
– –
TXMD icon
16
TherapeuticsMD
TXMD
$25.7M
$3.77M 1.04%
16,930
– –
LPCN icon
17
Lipocine
LPCN
$18.4M
$3.52M 0.97%
39,407
– –
VIRX
18
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.37M 0.38%
+2,553
New +$1.15M
NBIX icon
19
Neurocrine Biosciences
NBIX
$15.8B
– –
-303,503
Closed -$4.76M
ALXA
20
DELISTED
Alexza Pharmaceuticals Inc
ALXA
– –
-71,212
Closed -$166K

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q4 2014 Portfolio in Review

As of Q4 2014, VHCP Management held 22 positions worth $364M, up 63% from $223M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

VHCP Management deployed $79.4M of net new capital in Q4 2014, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was Juno Therapeutics, Inc.: 1,749,999 shares worth $74.3M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 64% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was DYAX CORPORATION, an estimated $12.5M trimmed.

  • VHCP Management's largest Q4 2014 buy was Juno Therapeutics, Inc.: 1,749,999 shares worth $74.3M.
  • VHCP Management added most to Stemline Therapeutics, Inc. in Q4 2014, an estimated $4.12M increase.
  • VHCP Management's biggest Q4 2014 reduction was DYAX CORPORATION, cutting an estimated $12.5M.
  • VHCP Management fully exited Neurocrine Biosciences in Q4 2014, selling an estimated $4.76M.
  • VHCP Management's ten largest holdings make up 87% of its $364M portfolio in Q4 2014.
  • VHCP Management opened 4 new positions and closed 2 in Q4 2014.
  • VHCP Management's portfolio value rose 63% quarter-over-quarter to $364M.

Based on VHCP Management's 13F filing for Q4 2014, filed 13 Feb 2015.